Back Hepatitis C

Hepatitis C

ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients

AbbVie's interferon-free 3D regimen containing ABT-450, ombitasvir, and dasabuvir led to sustained virological response in nearly 100% of people with genotype 1b chronic hepatitis C regardless of unfavorable patient or viral characteristics, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

ICAAC 2014: AbbVie 3D Combination Works Well for People with HIV/HCV Coinfection

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks led to sustained virological response in 94% of HIV positive people with mostly genotype 1a hepatitis C coinfection in the TURQUOISE-I study, according to data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.

alt

Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment

An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.

alt

European Regulators Approve Daclatasvir for Hepatitis C

The European Medicines Agency, which handles regulatory approval for 28 countries of the European Union, this week approved Bristol-Myers Squibb's hepatitis C virus NS5A inhibitor daclatasvir (Daklinza) for use in combination therapy for HCV genotypes 1, 2, 3, and 4.

alt

New Hepatitis C Guidelines: Who Should Be Treated and When?

Everyone with chronic hepatitis C could potentially benefit from treatment with new direct-acting antivirals, but when resources are limited, people with advanced liver disease, those at greatest risk for complications, and those most likely to transmit HCV should be treated most urgently, according to new guidelines released this week from AASLD, IDSA, and IAS-USA.

alt

Achillion HCV NS5A Inhibitor + Sofosbuvir Shows High Early Cure Rate

An interferon-free dual combination of Achillion's hepatitis C virus NS5A inhibitor ACH-3012 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 8 weeks led to sustained virological response at 4 weeks post-treatment for people with HCV genotype 1 in a Phase 2 study, according to a company announcement.

alt

New Treatments Could Dramatically Reduce Hepatitis C Burden

Widespread screening and use of new direct-acting antivirals could make hepatitis C a rare disease within the next 2 decades, according to results from a mathematical modeling study published in the August 5 edition of Annals of Internal Medicine. Universal screening and treatment could prevent more than 161,000 liver-related deaths, they projected.

alt

Vertex to Discontinue Sale of Telaprevir (Incivek) for Hepatitis C

Vertex Pharmaceuticals announced last week that it will stop selling its HCV protease inhibitor telaprevir (Incivek or Incivo) as of October 16, 2014. While the first generation direct-acting antivirals are more effective than pegylated interferon plus ribavirin alone, they are no match for newer drugs such as Gilead Sciences' sofosbuvir (Sovaldi) or AbbVie's forthcoming "3D" regimen in terms of efficacy or tolerability.

alt

July 28 Is World Hepatitis Day [VIDEO]

July 28 is World Hepatitis Day, an opportunity to raise awareness about viral hepatitis and its consequences. This year's theme -- "Think Again" -- emphasizes that while hepatitis B and C are major causes of death worldwide, viral hepatitis remains remarkably neglected. The World Health Organization (WHO) and others held a press briefing at the 20th International AIDS Conference last week in Melbourne to raise awareness.

alt